Last reviewed · How we verify
Zavegepant 100mg immediate release tablet (zavegepant-100mg-immediate-release-tablet)
Zavegepant is a migraine treatment developed by Pfizer Inc. It is an immediate release tablet available in 100mg dosage. Zavegepant is used for the acute treatment of migraine with or without aura in adults. The exact mechanism of action is not specified. However, it is likely to target a specific molecular pathway involved in migraine. Zavegepant has the potential to provide relief for individuals experiencing migraines. Further research and clinical trials are needed to fully understand its effects and benefits.
At a glance
| Generic name | zavegepant-100mg-immediate-release-tablet |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | calcitonin gene-related peptide receptor antagonist |
| Target | calcitonin gene-related peptide receptor (CGRPR) |
| Phase | FDA-approved |
Approved indications
- Acute treatment of migraine with or without aura in adults
Common side effects
Drug interactions
- Warfarin
- Aspirin
- Pregabalin
- Opioids
- Benzodiazepines
- CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)
- CYP3A4 inducers (e.g., rifampin, carbamazepine)
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zavegepant 100mg immediate release tablet CI brief — competitive landscape report
- Zavegepant 100mg immediate release tablet updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI